[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP: Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res; 2002 May;8(5):1271-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of HER-2/neu in uterine serous papillary cancer.
  • PURPOSE: Uterine serous papillary carcinoma (USPC) is a highly aggressive variant of endometrial cancer and histologically similar to high-grade ovarian cancer.
  • In addition, we have tested the sensitivity of USPC cells to Herceptin treatment.
  • Fresh and established primary USPC cell lines were found to express significantly more HER-2/neu receptor by flow cytometry (on the average, 10-fold greater) when compared with HER-2/neu-positive primary or established breast and ovarian cancer cell lines (P < 0.001).
  • Importantly, although these USPC cell lines were resistant to chemotherapy in vivo and to natural killer- and complement-mediated cytotoxicity in vitro, they were found to be highly sensitive to Herceptin-mediated ADCC.
  • CONCLUSIONS: On the basis of these findings and previous reports showing a positive in vivo correlation between efficacy of Herceptin therapy and the level of HER-2/neu overexpression by tumor cells, we propose that Herceptin might be a novel and attractive therapeutic strategy in patients harboring chemotherapy-resistant, recurrent, or metastatic USPC.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Receptor, ErbB-2 / biosynthesis. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / pharmacology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Division / drug effects. Female. Flow Cytometry. Humans. Immunohistochemistry. Interleukin-2 / pharmacology. Killer Cells, Natural / immunology. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Rituximab. Trastuzumab. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / immunology. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12006548.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Interleukin-2; 4F4X42SYQ6 / Rituximab; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


2. Yoney A, Kucuk A, Alan O, Unsal M: A retrospective study of treatment and outcome in 39 cases of male breast cancer. Hematol Oncol Stem Cell Ther; 2008 Apr-Jun;1(2):98-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of treatment and outcome in 39 cases of male breast cancer.
  • BACKGROUND AND OBJECTIVES: Optimal management if male breast cancer (MBC) is not clearly established and treatment guidelines are scarce.
  • We evaluated our own results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognostic factors for survival.
  • PATIENTS AND METHODS: Thirty-nine patients with MBC were retrospectively studied to evaluate the results in this type of tumor; 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobuler carcinoma (ILC).
  • The distribution according to stage was 12.8%, 46.2%, 30.7% and 10.3% in Stages I, II, III and IV, respectively; 7.7% underwent radiotherapy (RT)+/-hormonotherapy (HT), 22.8% had chemotherapy (CT), 61.8% had chemoradiotherapy (CRT)+/-HT and 7.7% had HT in addition to surgery.
  • In a univariate analysis for OS, statistical significance was found for lymph node metastases (P=.00001), stage (P=.0098) and age (P=.03), while presence of RT in the treatment modality (P=.6849), and tumor size (P=.4439) demonstrated no significance.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy. Carcinoma / mortality. Carcinoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Male. Mastectomy. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063538.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Kameda C, Tanaka H, Yamasaki A, Nakamura M, Koga K, Sato N, Kubo M, Kuroki S, Tanaka M, Katano M: The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res; 2009 Mar;29(3):871-9
Hazardous Substances Data Bank. CYCLOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer.
  • Understanding the expression patterns of estrogen receptor-alpha (ERalpha) is essential for determining therapeutic strategies for patients with breast cancer.
  • The prognosis of patients with ERalpha-negative breast cancer is still poor.
  • We have previously shown that Hedgehog (Hh) signaling is constitutively activated in breast cancer and that Hh signaling could be a new therapeutic target.
  • Therefore, in this study, whether or not Hh signaling could be utilized as a therapeutic target for patients with ERalpha-negative breast cancer was examined.
  • For this purpose, three ERalpha-negative breast cancer cell lines were used in which Hh pathway-related molecules such as the ligand Patched1 and the transcriptional factor Gli1 as target cells are expressed.
  • Since our previous data have shown a constitutive activation of the Hh pathway in surgically-resected ERalpha-negative breast cancer specimens, the Hh pathway, especially Gli1, may be a useful therapeutic target for patients with ERalpha-negative breast cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma, Papillary / metabolism. Estrogen Receptor alpha / metabolism. Hedgehog Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Aged. Cell Proliferation / drug effects. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Tumor Cells, Cultured. Veratrum Alkaloids / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414322.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / estrogen receptor alpha, human; ZH658AJ192 / cyclopamine
  •  go-up   go-down


Advertisement
4. Ikeda M, Tanaka K, Sonoo H, Miyake A, Yamamoto Y, Shiiki S, Nakashima K, Kurebayashi J: [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma]. Gan To Kagaku Ryoho; 2007 Jun;34(6):933-6
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma].
  • We report three radioiodine-resistant patients with metastatic papillary thyroid carcinoma administered docetaxel.
  • Patient 1: Bi-weekly docetaxel was administered to a 67-year-old woman with clavicle, cervical lymph node and lung metastases that had progressed after external irradiation and radioiodine therapy.
  • Patient 2: Bi-weekly docetaxel was administered to a 72-year-old man with lung metastases that had progressed after radioiodine therapy.
  • Patient 3: Bi-weekly docetaxel was administered to a 58-year-old woman with lung metastases that had progressed after radioiodine therapy.
  • In all three patients, doubling time of tumor growth was revealed to be far prolonged after docetaxel administration without distinct adverse events.
  • Since no effective systemic treatment has been established for radioiodine-resistant patients with metastatic papillary thyroid carcinoma,docetaxel therapy was supposed to be a viable alternative for them.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Papillary / drug therapy. Taxoids / administration & dosage. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Iodine Radioisotopes. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565260.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / Taxoids; 15H5577CQD / docetaxel; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


5. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol; 2003 Dec;91(3):463-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
  • OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at a single institution.
  • The median age at the time of diagnosis was 68 years (range, 44-93 years).
  • A personal history of breast cancer was reported by 12.4% of the patients, and a family history of breast cancer was reported by 16%.
  • Among stage III patients, those who received chemotherapy had a longer OS than those who did not receive chemotherapy (P = 0.03).
  • CONCLUSION: In this population of nonselected patients with UPSC, approximately 20% had a personal or family history of breast cancer.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2003 Dec;91(3):461-2 [14675662.001]
  • (PMID = 14675663.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


6. Nakamura S, Kenjo H, Nishio T, Kazama T, Doi O, Suzuki K: Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy. Breast Cancer; 2002;9(1):15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy.
  • BACKGROUND: One of the main roles of neoadjuvant chemotherapy for breast cancer is to shrink large tumors to increase patient eligibility for breast conserving surgery.
  • Three dimensional MR Mammography (3D-MRM) can detect tumor extension more accurately compared with mammography and Ultrasonography (US).
  • METHODS: A total of 27 breast cancer cases were examined by 3D-MRM before and after neoadjuvant chemotherapy.
  • Twelve of 25 evaluable breast cancers (48%) showed a concentric shrinkage pattern while 13 cases (52%) showed a dendritic shrinkage pattern.
  • The cases with concentric shrinkage were good candidates for breast conserving surgery, But tumors showing dendritic shrinkage often had positive margins necessitating mastectomy.
  • CONCLUSIONS: 3D-MRM is a useful modality for evaluating whether breast conserving surgery can be safely done in the neoadjuvant setting.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology. Magnetic Resonance Imaging / standards. Mammography / standards
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Imaging, Three-Dimensional. Mastectomy, Segmental. Neoadjuvant Therapy. Neoplasm Staging / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12196716.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


7. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD: Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer; 2010 Jul 02;10:349
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
  • BACKGROUND: Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer remains a high priority.
  • METHODS: Because claudin-3 and -4 are the epithelial receptors for Clostridium perfringens enterotoxin (CPE), and are sufficient to mediate CPE binding, in this study we evaluated the in vitro and in vivo bioactivity of the carboxy-terminal fragment of CPE (i.e., CPE290-319 binding peptide) as a carrier for tumor imaging agents and intracellular delivery of therapeutic drugs.
  • Cell binding assays were used to assess the accuracy and specificity of the CPE peptide in vitro against primary chemotherapy-resistant ovarian carcinoma cell lines.
  • Confocal microscopy and biodistribution assays were performed to evaluate the localization and uptake of the FITC-conjugated CPE peptide in established tumor tissue.
  • RESULTS: Using a FITC-conjugated CPE peptide we show specific in vitro and in vivo binding to multiple primary chemotherapy resistant ovarian cancer cell lines.
  • Bio-distribution studies in SCID mice harboring clinically relevant animal models of chemotherapy resistant ovarian carcinoma showed higher uptake of the peptide in tumor cells than in normal organs.
  • Imunofluorescence was detectable within discrete accumulations (i.e., tumor spheroids) or even single chemotherapy resistant ovarian cancer cells floating in the ascites of xenografted animals while a time-dependent internalization of the FITC-conjugated CPE peptide was consistently noted in chemotherapy-resistant ovarian tumor cells by confocal microscopy.
  • CONCLUSIONS: Based on the high levels of claudin-3 and -4 expression in chemotherapy-resistant ovarian cancer and other highly aggressive human epithelial tumors including breast, prostate and pancreatic cancers, CPE peptide holds promise as a lead peptide for the development of new diagnostic tracers or alternative anticancer agents.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):262-70 [11782386.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Infect Immun. 1975 Aug;12(2):440-2 [168155.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1801-7 [2418017.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):630-4 [7906395.001]
  • [Cites] Toxicon. 1996 Nov-Dec;34(11-12):1335-43 [9027990.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7977-82 [17804705.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9 [19426958.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20598131.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Cldn3 protein, mouse; 0 / Cldn4 protein, mouse; 0 / Enterotoxins; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / enterotoxin, Clostridium
  • [Other-IDs] NLM/ PMC2908101
  •  go-up   go-down


8. Bartels PH, Montironi R, Scarpelli M, Bartels HG, Alberts DS: Knowledge discovery processing and data mining in karyometry. Anal Quant Cytol Histol; 2009 Jun;31(3):125-36
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Clinical materials and results from the analysis of 4 studies were used: the demonstration of chemopreventive efficacy of letrozole in a situation where only a small subset of cells is affected, the detection of a preneoplastic lesion in colorectal tissue, data processing to document clues that predict risk of recurrence of a bladder lesion and the use of metafeatures and second-order discriminant analysis in a study of efficacy of vitamin A in the chemoprevention of skin lesions.
  • RESULTS: Evidence for chemopreventive efficacy was demonstrated in the first example only after processing identified the small subpopulation of affected nuclei in a study of breast epithelial cells.
  • Detection of a preneoplastic development is linked to a progression curve connecting nuclei from normal tissue to nuclei from premalignant colorectal lesions.
  • The prediction of risk of recurrence of papillary bladder lesions is possible by detecting changes in nuclei of a certain phenotype.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):300-12 [11531145.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Aug;24(4):185-97 [12199319.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):893-901 [14562285.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):339-46 [14714300.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):928-37 [15105811.001]
  • [Cites] Anal Quant Cytol. 1984 Dec;6(4):247-61 [6397084.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2704-16 [18086777.001]
  • [Cites] Pathologica. 1995 Jun;87(3):286-99 [8570289.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1875-88 [16087328.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Oct;28(5):243-52 [17067006.001]
  • [Cites] Cell Oncol. 2007;29(1):47-58 [17429141.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Apr;29(2):63-70 [17484269.001]
  • [Cites] Cytometry. 1986 Sep;7(5):467-74 [3757694.001]
  • (PMID = 19634783.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P30 CA23074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ NIHMS584893; NLM/ PMC4029779
  •  go-up   go-down


9. Nio Y, Toga T, Maruyama R, Fukushima M: Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep; 2007 Jul;18(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
  • The enzyme orotate phosphoribosyl transferase (OPRT) is involved in the metabolism of the anticancer drug 5-fluorouracil (5-FU), and is a key enzyme for conversion of 5-FU to its active form in tumor tissue.
  • The present study was designed to assess the association between the activity of OPRT in the tumor, and the clinicopathological status and prognosis of human resectable pancreatic cancer, especially regarding its relevance to the efficacy of adjuvant chemotherapy with uracil and tegafur (UFT), cyclophosphamide (CPA) and/or gemcitabine (GEM).
  • In the OPRT (+) group, the survival rate of the patients, who received adjuvant chemotherapy (ACT) with UFT, CPA or GEM, was significantly higher than that of the patients without ACT; however, in the OPRT (-) group, there was no difference in the survival between the ACT (+) and (-) groups.
  • Multivariate analyses demonstrated that for all patients, primary tumor, status of nodal involvement (pN), residual tumor, level of dissection and CPA were significant variables for the prognosis: in OPRT (+) groups, primary tumor, nodal involvement, GEM and CPA were significant variables.
  • The present study is the first report on the significance of OPRT in human pancreatic cancer, and the results indicate that the expression of OPRT may be useful to predict the response to adjuvant chemotherapy in human pancreatic cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / enzymology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Papillary / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549346.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Mirza IA, Shahab N: Small cell carcinoma of the breast. Semin Oncol; 2007 Feb;34(1):64-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the breast.
  • Small cell carcinoma of the breast (SCCB) is an uncommon neoplasm that accounts for less than 1% of primary breast cancers.
  • Histologically, these tumors have striking similarities to small call carcinoma of the lung, usually with evidence of associated ductal carcinoma-in-situ (DCIS) with areas of ductal, lobular, or papillary differentiation.
  • Treatment, which may include surgery, radiotherapy, and combination chemotherapy, is based on clinical stage and the presence of metastases.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Small Cell
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270668.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Number-of-references] 34
  •  go-up   go-down


11. Yoney A, Kucuk A, Unsal M: Male breast cancer: a retrospective analysis. Cancer Radiother; 2009 Apr;13(2):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer: a retrospective analysis.
  • BACKGROUND: To evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.
  • PATIENTS AND METHODS: Thirty-nine patients with male breast cancer have been retrospectively studied with the trial aim to evaluate the results of our practice.
  • Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively.
  • Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.
  • In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p=0.00001), stage (p=0.0098) and age (p=0.03); while RT in the treatment modality (p=0.6849), and tumor size (p=0.4439) demonstrated no significance.
  • CONCLUSION: Postoperative radiotherapy was important in the management of male breast cancer to improve LC resulting in one local failure, but did not improve OS and DFS in our analysis.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250851.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Chen L, Fan Y, Lang RG, Guo XJ, Sun YL, Fu L: [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. Zhonghua Bing Li Xue Za Zhi; 2007 Apr;36(4):228-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and prognosis study of breast carcinoma with micropapillary component].
  • OBJECTIVE: To study the diagnostic criteria, clinicopathologic characteristics and prognosis of invasive micropapillary carcinoma (IMPC) of breast.
  • METHODS: All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed.
  • One hundred examples with IMPC component, according to the 2003 World Health Organization classification of breast tumors, were identified.
  • Univariate and multivariate analysis showed that the prognosis of patients was adversely affected by the presence of lymphovascular invasion and family history of breast cancer.
  • On the other hand, tamoxifen therapy and adjuvant chemotherapy improved survival.
  • CONCLUSIONS: Breast carcinoma with IMPC component is associated with poor prognosis, despites the relative proportion of this architectural pattern.
  • The overall prognosis is related to the presence of lymphovascular invasion and family history of breast cancer.
  • Hormonal therapy and individualized chemotherapy can improve the survival rate.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Papillary / diagnosis. Mastectomy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genetic Predisposition to Disease. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706112.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


13. Xue Y, Guo XT, Liu WC: [Clinical research advancement on male breast cancer]. Ai Zheng; 2007 Oct;26(10):1148-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research advancement on male breast cancer].
  • Male breast cancer is a rare disease and the incidence has increased over the past 25 years.
  • Current knowledge regarding its biology, natural history, and treatment strategies is mainly based on the research findings on female breast cancer.
  • Hormonal imbalances, such as gonadal dysfunction, obesity, and radiation exposure also contribute to the occurrence of male breast cancer.
  • Indications for radiotherapy, as well as the steps and methods, are similar to that for female breast cancer.
  • Because 90% of the patients are estrogen receptor-positive, tamoxifen is a standard adjuvant therapy, but some individuals could also benefit from chemotherapy.
  • In this article, the latest information on the epidemiology, biology, and treatment of male breast cancer is reviewed.
  • [MeSH-major] Breast Neoplasms, Male / therapy. Carcinoma, Ductal, Breast / therapy. Mastectomy / methods. Tamoxifen / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis Regulatory Proteins. BRCA2 Protein / genetics. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Humans. Male. Methotrexate / therapeutic use. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927890.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol
  • [Number-of-references] 47
  •  go-up   go-down


14. Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G: Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol; 2004 Jun;121(6):857-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior.
  • We report 62 cases of invasive micropapillary carcinoma of the breast characterized by delicate pseudopapillary structures lacking a fibrovascular core and by tubuloalveolar structures freely floating in clear, empty spaces.
  • Tumor size ranged from 0.7 to 10 cm (median, 2.8 cm); 54 (87%) were grade 3.
  • These results underscore the aggressive behavior and poor prognosis of this breast carcinoma variant.
  • Aggressive preoperative neoadjuvant chemotherapy should be considered.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / pathology. Cadherins / metabolism. Female. Genes, erbB-2. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Recurrence, Local / pathology. Ploidies. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


15. Kurosumi M, Tabei T, Inoue K, Takei H, Ninomiya J, Naganuma R, Suemasu K, Higashi Y, Tsuchiya E: Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients. Oncol Rep; 2003 Jul-Aug;10(4):833-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients.
  • This study aimed to determine the prognostic significance of histological scoring system based on heterogeneity of invasive ductal carcinoma, for node-negative breast cancer patients.
  • We studied 108 patients of node-negative invasive ductal carcinoma with invasive tumor >5 mm.
  • These results suggested that assessment of histological heterogeneity of invasive ductal carcinoma could serve as independent potent prognostic factor for node-negative invasive ductal carcinoma of the breast, and this method might be useful to decide indication of postoperative adjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / classification. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Scirrhous / classification. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792731.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


16. Fowler AM, Andersen JJ, Conway PD: Local recurrence of invasive micropapillary breast cancer after MammoSite brachytherapy: a case report and literature review. Clin Breast Cancer; 2009 Nov;9(4):253-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence of invasive micropapillary breast cancer after MammoSite brachytherapy: a case report and literature review.
  • Controversy exists over the optimal patient selection criteria for accelerated partial-breast irradiation (APBI), which has been introduced as an alternative to whole-breast irradiation.
  • The goal is to select patients with the lowest risk for tumor spread outside of the original lumpectomy bed targeted by the local internal radiation dose.
  • Therefore, patients with more aggressive types of breast cancer might not be ideal candidates for partial breast irradiation.
  • We discuss the case of a 67-year-old woman who presented with local recurrence of invasive micropapillary breast cancer, a rare aggressive tumor type, 5 years after MammoSite brachytherapy.
  • The patient's primary tumor possessed all favorable indicators except for the histology of invasive micropapillary carcinoma.
  • Although this is a single case, it supports the hypothesis that more aggressive types of breast cancer have a higher risk of local recurrence after APBI.
  • More aggressive treatment approaches including whole-breast irradiation and/or chemotherapy might be needed to reduce the risk of local recurrence for invasive micropapillary breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiotherapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Brachytherapy. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933082.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


18. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol; 2008 Apr;129(4):563-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
  • We performed a technical and cost-effectiveness analysis of quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) for the assessment of HER2 in breast cancer.
  • We evaluated 44 frozen and 55 formalin-fixed paraffin-embedded (FFPE) breast carcinoma specimens by Q-RT-PCR, immunohistochemical analysis, and fluorescent in situ hybridization (FISH).
  • Immunohistochemical and FISH analyses were performed on individual slides and on tissue microarray.
  • Cost analysis documented the advantage of Q-RT-PCR in all US Food and Drug Administration-approved assays.
  • Our data support the use of Q-RT-PCR for testing breast cancer specimens to select patients for HER2 inhibitory therapy.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction / economics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cost-Benefit Analysis. Female. Gene Expression. Humans. In Situ Hybridization, Fluorescence / economics. In Situ Hybridization, Fluorescence / methods. Middle Aged. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / metabolism. Sweat Gland Neoplasms / pathology. Tissue Array Analysis / economics. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343783.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


19. Leboeuf R, Bénard F, Langlois MF: Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid. Clin Nucl Med; 2006 Jul;31(7):382-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
  • INTRODUCTION: Metastases to the thyroid gland are considered a rare cause of thyroid tumor.
  • Furthermore, a relationship between breast and thyroid carcinoma has been previously proposed.
  • CASE DESCRIPTION: We describe the case of a 59-year-old woman who presented with simultaneous papillary and breast carcinoma within the thyroid gland.
  • F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) done for the evaluation of her metastatic breast cancer revealed a thyroid incidentaloma with a high metabolic rate (standardized uptake value [SUV] of 13).
  • She underwent thyroidectomy and the pathology revealed papillary thyroid carcinoma corresponding to the lesion visualized on FDG PET.
  • However, small metastatic implants of breast carcinoma were seen within the opposite thyroid lobe.
  • CONCLUSION: This is a rare description of a concomitant papillary thyroid carcinoma presenting as an FDG PET incidentaloma alongside breast cancer metastases to the thyroid gland.
  • Thyroid and breast cancer sometimes occur in the same patient.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / radionuclide imaging. Estrogens. Incidental Findings. Neoplasms, Hormone-Dependent / radionuclide imaging. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mastectomy, Segmental. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Middle Aged. Neoplasm Proteins / analysis. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / radiography. Neoplasms, Radiation-Induced / radionuclide imaging. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785803.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Cortesi L, De Matteis E, Rashid I, Cirilli C, Proietto M, Rivasi F, Federico M: Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer; 2009 Nov;19(8):1358-63
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study.
  • INTRODUCTION: The aim of this study was to investigate the incidence of second primary tumors in patients with breast cancer (BC), with particular regard to bidirectional risk for endometrial cancer (EC).
  • RESULTS: A total of 499 women with primary BC developed a second tumor.
  • [MeSH-major] Breast Neoplasms / epidemiology. Endometrial Neoplasms / epidemiology. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Incidence. Italy / epidemiology. Middle Aged. Neoplasm Staging. Prognosis. Registries. Risk Factors. Survival Rate. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009890.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


21. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • Preoperative diagnosis of fallopian tube carcinoma is difficult due to the rarity and silent course of this neoplasm.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Cystadenocarcinoma, Papillary / diagnosis. Fallopian Tube Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


22. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd: Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol; 2006 Feb;100(2):437-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
  • BACKGROUND: Paclitaxel is one of the most active agents in the treatment of ovarian carcinoma.
  • CASE: We present a case involving a 60-year-old ovarian cancer patient with a significant history of chemotherapy induced HSR.
  • She underwent optimal cytoreductive surgery and began adjuvant chemotherapy in 2000 until she suffered a severe HSR to paclitaxel.
  • In 2002, she was diagnosed with recurrent disease and underwent subsequent treatment with carboplatin, cisplatin, and doxorubicin, all of which resulted in severe HSR.
  • The patient began abraxane therapy in 2005 and has shown no signs of HSR.
  • CONCLUSION: Abraxane is a solvent free taxane, which can be administered without the pre-medications routinely used to prevent HSR.
  • Abraxane may offer paclitaxel HSR patients the benefit of continued taxane treatment.
  • Although the clinical activity of abraxane has not been extensively investigated in ovarian carcinoma, the distinct activity of paclitaxel and good results with recurrent metastatic breast cancer patients suggest additional evaluation with this drug is important.
  • [MeSH-major] Drug Hypersensitivity / etiology. Ovarian Neoplasms / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / adverse effects. Albumins / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226797.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Kolwijck E, Boss EA, van Altena AM, Beex LV, Massuger LF: Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: a case report and review of the literature. Gynecol Oncol; 2007 Dec;107(3):583-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We describe an 18-year-old girl presenting with umbilical metastasis as a first sign of an extremely aggressive stage IV ovarian serous papillary adenocarcinoma without an objective response to chemotherapy and endocrine therapy.
  • She developed metastasis in both breasts and died 28 months after the initial diagnosis.
  • Furthermore, uncommon breast metastasis and a Sister Mary Joseph's nodule have never been described at such young age.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Umbilicus / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Adolescent. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / secondary. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904207.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Dovedi SJ, Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev; 2009 Dec;28(3-4):355-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
  • The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years.
  • Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors such as lung, breast and prostate, been few in number and largely unsuccessful, with no new agents being registered in the last 20 years.
  • Hence, bladder cancer represents a considerable opportunity and challenge for molecularly targeted therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Transitional Cell / drug therapy. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Angiogenesis Inhibitors / therapeutic use. BCG Vaccine / administration & dosage. BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma in Situ / economics. Carcinoma in Situ / epidemiology. Carcinoma in Situ / immunology. Carcinoma in Situ / surgery. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / economics. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / immunology. Carcinoma, Papillary / surgery. Cell Cycle / drug effects. Clinical Trials as Topic. Combined Modality Therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Cystectomy. Disease Management. Genetic Therapy. Humans. Intercellular Signaling Peptides and Proteins. Neoplasm Invasiveness. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / physiology. Neovascularization, Pathologic / drug therapy. Signal Transduction / drug effects. Tumor Suppressor Protein p53 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997963.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 0 / Cyclooxygenase 2 Inhibitors; 0 / Drugs, Investigational; 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 105
  •  go-up   go-down


25. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, Anantharamaiah GM, Van Lenten BJ, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R: Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A; 2010 Nov 16;107(46):19997-20002
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.
  • Mice expressing a human apoA-I transgene had (i) increased survival (P < 0.0001) and (ii) decreased tumor development (P < 0.01), when compared with littermates, following injection of mouse ovarian epithelial papillary serous adenocarcinoma cells (ID-8 cells).
  • ApoA-I mimetic peptides reduced viability and proliferation of ID8 cells and cis-platinum-resistant human ovarian cancer cells, and decreased ID-8 cell-mediated tumor burden in C57BL/6J mice when administered subcutaneously or orally.
  • Serum levels of lysophosphatidic acid, a well-characterized modulator of tumor cell proliferation, were significantly reduced (>50% compared with control mice, P < 0.05) in mice that received apoA-I mimetic peptides (administered either subcutaneously or orally), suggesting that binding and removal of lysophosphatidic acid is a potential mechanism for the inhibition of tumor development by apoA-I mimetic peptides, which may serve as a previously unexplored class of anticancer agents.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Water .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2000 Apr;21(4):585-91 [10753190.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):102-5 [20698078.001]
  • [Cites] Circulation. 2002 Jan 22;105(3):290-2 [11804981.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Circulation. 2002 Aug 27;106(9):1127-32 [12196340.001]
  • [Cites] Vascul Pharmacol. 2002 Apr;38(4):211-8 [12449017.001]
  • [Cites] J Nutr Biochem. 2003 Feb;14(2):64-73 [12667597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 19;309(2):377-83 [12951060.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8 [14523236.001]
  • [Cites] Circulation. 2004 Jun 29;109(25):3215-20 [15197147.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91 [15247129.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1676-81 [15242861.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3884-8 [8033111.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Haematologica. 1996 Jul-Aug;81(4):343-45 [8870380.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):379-84 [9669823.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R640-6 [15535846.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):524-32 [16100046.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39485-92 [16179351.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1190-7 [16224061.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Jan;15(1):13-21 [16370930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9643-8 [16769891.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):284-93 [17270017.001]
  • [Cites] Pancreas. 2007 Mar;34(2):205-14 [17312459.001]
  • [Cites] J Lipid Res. 2007 Nov;48(11):2344-53 [17693626.001]
  • [Cites] Methods Enzymol. 2007;433:1-25 [17954226.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):573-9 [17674197.001]
  • [Cites] J Lipid Res. 2008 Aug;49(8):1658-69 [18426778.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Lipid Res. 2008 Nov;49(11):2302-11 [18621920.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Nov;9(11):1157-62 [18951294.001]
  • [Cites] Curr Atheroscler Rep. 2009 Jan;11(1):52-7 [19080728.001]
  • [Cites] Curr Atheroscler Rep. 2009 Jan;11(1):58-63 [19080729.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):64-74 [19139114.001]
  • [Cites] J Lipid Res. 2009 Feb;50(2):204-13 [18812596.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):481-5 [19101714.001]
  • [Cites] Curr Opin Lipidol. 2009 Apr;20(2):157-8 [19276898.001]
  • [Cites] Neurobiol Dis. 2009 Jun;34(3):525-34 [19344763.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] J Lipid Res. 2009 Jul;50(7):1293-304 [19224872.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1692-701 [19509252.001]
  • [Cites] J Biol Chem. 2009 Jul 3;284(27):18292-301 [19433579.001]
  • [Cites] J Lipid Res. 2009 Aug;50(8):1538-47 [19225094.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H866-73 [19561306.001]
  • [Cites] Kidney Int. 2009 Aug;76(4):437-44 [19471321.001]
  • [Cites] Kidney Int. 2009 Aug;76(4):359-61 [19644477.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3191-8 [19755862.001]
  • [Cites] Gynecol Oncol. 2010 Jan;116(1):78-81 [19822357.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):164-8 [19608977.001]
  • [Cites] Cancer. 2010 Feb 1;116(3):544-73 [19998273.001]
  • [Cites] Antioxid Redox Signal. 2010 Apr 15;12(8):1009-59 [19686040.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • (PMID = 21041624.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL030568; United States / NHLBI NIH HHS / HL / R01 HL082823; United States / NHLBI NIH HHS / HL / HL-082823; United States / NHLBI NIH HHS / HL / HL-30568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Lysophospholipids; 0 / Peptides; 059QF0KO0R / Water; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2993420
  •  go-up   go-down


26. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK: Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid; 2010 Jan;20(1):33-41
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of thyroid malignancies are three to four times higher in women, suggesting the possible involvement of estrogen.
  • These findings will enable and foster the possible development of antiestrogenic therapy targeting invasion and migration, thus affecting metastatic propensity.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1993 Jul-Aug;50(4):309-15 [8497382.001]
  • [Cites] Curr Opin Obstet Gynecol. 2009 Jun;21(3):291-5 [19469047.001]
  • [Cites] Ann N Y Acad Sci. 1997 Dec 29;833:129-36 [9616745.001]
  • [Cites] Ann Surg Oncol. 2004 Dec;11(12):1093-7 [15576834.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6466-75 [16024652.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 25;337(3):1019-25 [16219298.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 10;340(2):718-25 [16380095.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 18;534(1-3):39-47 [16497293.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2038-48 [16609013.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):984-8 [16831055.001]
  • [Cites] J Nutr Biochem. 2006 Oct;17(10):659-64 [16488130.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):11-7 [17133106.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):11-21 [17197171.001]
  • [Cites] Nat Protoc. 2007;2(2):329-33 [17406593.001]
  • [Cites] Histopathology. 2008 Jan;52(1):82-90 [18171419.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):957-60 [18281467.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Am Surg. 2008 May;74(5):389-99 [18481494.001]
  • [Cites] PLoS One. 2008;3(5):e2238 [18493596.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Jul;4(7):394-405 [18506157.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6038-42 [18676823.001]
  • [Cites] Clin Obstet Gynecol. 2008 Sep;51(3):592-606 [18677153.001]
  • [Cites] Radiol Technol. 2009 Jan-Feb;80(3):241-61 [19153200.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):570-4 [19155436.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1174-82 [19293308.001]
  • [Cites] Med J Aust. 2004 Mar 1;180(5):242-7 [14984346.001]
  • [Cites] Altern Med Rev. 2002 Apr;7(2):112-29 [11991791.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4268-72 [11549660.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7 [11238488.001]
  • [Cites] Postgrad Med J. 2000 Sep;76(899):529-36 [10964113.001]
  • [Cites] J Mol Med (Berl). 2000;78(3):155-65 [10868478.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5705-11 [10579335.001]
  • [Cites] Cancer. 2009 Aug 15;115(16):3801-7 [19598221.001]
  • [Cites] Breast Cancer Res. 2009;11(3):206 [19519952.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):1051-61 [19432902.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 19;384(1):6-11 [19379710.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):126-31 [8271295.001]
  • (PMID = 20067378.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131946-03; United States / NCI NIH HHS / CA / R01 CA131946; United States / NCI NIH HHS / CA / 1R01CA131946-01A2; United States / NCI NIH HHS / CA / CA131946-02; United States / NCI NIH HHS / CA / R01 CA131946-02; United States / NCI NIH HHS / CA / CA131946-01A2; United States / NCI NIH HHS / CA / R01 CA131946-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / HSP90 Heat-Shock Proteins; 0 / beta Catenin; 4TI98Z838E / Estradiol; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2833180
  •  go-up   go-down


27. Horii R, Akiyama F: [Histological features of breast cancer as predictive factors for chemotherapy]. Nihon Rinsho; 2007 Jun 28;65 Suppl 6:160-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological features of breast cancer as predictive factors for chemotherapy].
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology. Forecasting
  • [MeSH-minor] Cell Nucleus / pathology. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679197.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 4
  •  go-up   go-down


28. Montagna E, Cancello G, Torrisi R, Rizzo S, Scarano E, Colleoni M: Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. Ann Oncol; 2010 Mar;21(3):667-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032127.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement